X4 PHARMACEUTICALS, INC Operating Lease Right-of-Use Assets
X4 PHARMACEUTICALS, INC (XFOR) had Operating Lease Right-of-Use Assets of $654.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $654.00K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.03M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.41M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.77M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $654.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.41M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.77M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.65M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $3.65M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $4.07M 10-K · filed 2026-03-17 |
| 2024-09-30 | $4.47M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $4.87M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.26M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $5.65M 10-K · filed 2025-03-26 |
| 2023-09-30 | $6.05M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $6.45M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $6.84M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $7.23M 10-K · filed 2024-03-21 |
| 2022-09-30 | $7.61M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $7.98M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $8.34M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $8.71M 10-K · filed 2023-03-21 |
| 2021-09-30 | $9.07M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $9.43M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $9.79M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $7.96M 10-K · filed 2022-03-17 |
| 2020-09-30 | $8.22M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.64M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $1.80M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.96M 10-K · filed 2021-03-19 |
| 2019-09-30 | $2.11M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $2.19M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $2.71M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |